Influence of Sodium Bicarbonate on Time-to-exhaustion at Critical Power in Endurance Athletes

This study has been completed.
Sponsor:
Collaborator:
Swiss Federal Institute of Technology
Information provided by (Responsible Party):
University of Zurich
ClinicalTrials.gov Identifier:
NCT01621074
First received: June 12, 2012
Last updated: April 11, 2013
Last verified: April 2013
  Purpose

During endurance exercise in the heavy and severe intensity domains, the rate at which metabolites that have been associated with the fatigue process (e.g. Pi, ADP, H, and extracellular K) accumulate increases. possibly leading to exercise cessation. Sodium bicarbonate, as a nutritional supplement, has gained attention over the past decades, because it might delay of offset fatigue. To date, there is a controversial discussion about which delivery mode (amount and frequency) might be best in optimizing endurance performance. Since the high ion load consequent to multiple ingestions might increase plasma volume, and consequently decrease bicarbonate concentrations, single acute ingestion could be more beneficial. However, in multi-day competitions or tournaments it might be necessary to use the supplement on a daily basis. Here, the investigators aim at investigating the effects of single dose or multiple dose (on five consecutive days) administration of bicarbonate vs. placebo increases endurance performance and acid-base homeostasis in trained male endurance athletes.


Condition Intervention
Performance
Dietary Supplement: Sodium bicarbonate
Dietary Supplement: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Outcomes Assessor)

Resource links provided by NLM:


Further study details as provided by University of Zurich:

Primary Outcome Measures:
  • Time-to-exhaustion [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]

Enrollment: 12
Study Start Date: October 2011
Study Completion Date: January 2013
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Sodium bicarbonate Dietary Supplement: Sodium bicarbonate
Ergogenic effect
Placebo Comparator: Placebo Dietary Supplement: Placebo
Placebo effect

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria: - male

  • no cold or temperature at beginning or during the study
  • between 18 and 45 years of age
  • active in endurance sports (3 to 5 times per week a moderate to hart training)
  • non-smoker
  • no known cardiovascular or orthopedic problems
  • no known limitations of kidney function
  • no bearer of a cardiac pacemaker
  • no medications with direct influence on the measurements. The whole intake of medicaments has to be declared in the health questionnaire by the participant.
  • requirements of the health questionnaire fulfilled

Exclusion criteria: - female

  • male and age under 18 or over 45 years
  • cold or temperature at the beginning or during the study
  • untrained (less than 3 moderate trainings per week)
  • smoker
  • cardiovascular or orthopedic problems
  • limitations of the kidney function
  • bearer of a cardiac pacemaker
  • medication with direct influence on the measurements. The whole intake of medicaments has to be declared in the health questionnaire by the participant.
  • requirements of the health questionnaire not fulfilled
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01621074

Locations
Switzerland
University Hospital Zurich, Division of Neurology
Zurich, ZH, Switzerland, 8091
Sponsors and Collaborators
University of Zurich
Swiss Federal Institute of Technology
Investigators
Study Director: Neurologie: Neurologische Forschung University Hospital Zurich, Division of Neurology
Principal Investigator: Marco Toigo, PhD Swiss Federal Institute of Technology Zurich
  More Information

No publications provided

Responsible Party: University of Zurich
ClinicalTrials.gov Identifier: NCT01621074     History of Changes
Other Study ID Numbers: nbc
Study First Received: June 12, 2012
Last Updated: April 11, 2013
Health Authority: Switzerland: Ethikkommission

ClinicalTrials.gov processed this record on October 29, 2014